Colorectal Cancer Prevention (PDQ®)
Daily aspirin (acetylsalicylic acid) significantly reduces the long‑term risk of developing colorectal cancer and of colorectal cancer mortality
The PDQ Cancer Information Summary for health professionals provides comprehensive, peer‑reviewed, evidence‑based information about colorectal cancer prevention. The summary reviews the epidemiology, risk factors, screening, and preventive interventions, with a focus on lifestyle factors, pharmacologic agents, and surveillance strategies for high‑risk populations.
Reducing the incidence and mortality of colorectal cancer improves survival rates, decreases healthcare costs, and lessens the burden of disease on patients and society.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics